Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar
-
ナレーター：
-
著者：
One trial. One therapy. Countless clinical questions.
In Episode 4 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar take a deep dive into the VIKTORIA-1 trial and discuss how gedatolisib may reshape treatment for patients with HR-positive, HER2-negative metastatic breast cancer.
Beyond reviewing the data, they explore where this regimen fits in clinical practice, who may benefit most, concerns surrounding toxicity and treatment burden, and how VIKTORIA-1 compares with other rapidly emerging therapies in this evolving treatment landscape.
Topics discussed:
VIKTORIA-1 trial design and key efficacy results
Gedatolisib triplet vs. doublet therapy
Managing HR-positive, HER2-negative metastatic breast cancer
Intravenous therapy vs. oral treatment options
Stomatitis and other treatment-related toxicities
Patient selection and co-mutations
How PAM pathway inhibition may overcome resistance
Sequencing endocrine therapies after progression
Emerging trials including FOURLIGHT-1 and selective CDK4 inhibitors
The future of targeted therapy in metastatic breast cancer
Recorded prior to the July 2026 FDA approval of gedatolisib (Revtorpyk) with fulvestrant, ± palbociclib, for HR-positive, HER2-negative advanced breast cancer without a detectable PIK3CA mutation after progression on prior endocrine therapy.
▶️ Watch on YouTube - https://youtu.be/43BVZ9nL424
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - https://linkin.bio/cancerunfilteredpodcast/
#CancerUnfiltered #VIKTORIA1 #Gedatolisib #HRPositive #MetastaticBreastCancer #MedicalOncology #BreastCancer #PI3K #PIK3CA #TargetedTherapy #CommunityHealthMedia